A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Summary

This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \[HER2\]-negative) breast cancer.

Timeline

Start

2022-10-05

Primary completion

2026-11

Completion

2026-11

Drugs

Indications